card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Shifting mindsets all around: clinical thinking about Alzheimer’s disease moves from symptoms treatment toward earlier intervention and prevention

Shifting mindsets all around: clinical thinking about Alzheimer’s disease moves from symptoms treatment toward earlier intervention and prevention
Home / Insights / Shifting mindsets all around: clinical thinking about Alzheimer’s disease moves from symptoms treatment toward earlier intervention and prevention

Alzheimer’s disease care is shifting from treating symptoms to focusing on early intervention and prevention. Advances in blood-based biomarkers, such as pTau181 and pTau217, now allow for earlier and less invasive diagnosis, enabling timely treatment and better clinical trial design. New disease-modifying drugs like lecanemab and donanemab show the greatest benefit when administered early, reinforcing the importance of proactive detection.

 

Researchers are also adopting a more systemic view of Alzheimer’s, exploring factors beyond the brain, including gut microbiome health, cholesterol metabolism, genetics, and mitochondrial function. Emerging tools like digital biomarkers and wearables, combined with updated diagnostic guidelines, empower clinicians and patients to act sooner. This evolving approach aims to move Alzheimer’s care toward prevention and personalized strategies, improving long-term outcomes and quality of life.

 

Use the link below to access the full article.

 


Download Document